Stoke Therapeutics, Inc

(NASDAQ:STOK)

Latest On Stoke Therapeutics, Inc (STOK):

Date/Time Type Description Signal Details
2023-05-04 17:05 ESTNewsStoke Therapeutics GAAP EPS of -$0.53 beats by $0.15, revenue of $5.15M beats by $1.65MN/A
2023-05-01 14:11 ESTNewsStoke Therapeutics upgraded to neutral at BoA on Dravet candidateN/A
2023-04-26 22:19 ESTNewsStoke Therapeutics a buy at Canaccord on platform for genetic diseasesN/A
2023-04-25 22:00 ESTNewsStoke stock rises after UK regulator nod to start trial of eye disorder drugN/A
2023-03-15 17:15 ESTNewsStoke gets FDA nod to use higher dose of epilepsy drug in ongoing trialN/A
2023-03-06 19:36 ESTNewsStoke Therapeutics GAAP EPS of -$0.65 beats by $0.05, revenue of $3.27M beats by $0.41MN/A
2023-02-12 09:04 ESTNewsStoke Therapeutics Looks Unfairly ValuedN/A
2022-11-28 18:27 ESTNewsBuy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet SyndromeN/A
2022-11-14 15:38 ESTNewsStoke Therapeutics GAAP EPS of -$0.66 beats by $0.02, revenue of $2.91M beats by $0.19MN/A
2022-11-14 15:37 ESTNewsStoke Therapeutics drops 27% after early data for anti-seizure medicineN/A
2022-08-09 08:23 ESTNewsStoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18MN/A
2022-05-10 14:29 ESTNewsStoke Therapeutics GAAP EPS of -$0.66 misses by $0.98, revenue of $3M misses by $34.5MN/A
2022-03-10 22:22 ESTNewsStoke Therapeutics GAAP EPS of -$0.66 misses by $0.04N/A
2022-01-31 23:13 ESTNewsStoke Therapeutics initiated Buy at Jefferies on potential of RNA platformN/A
2022-01-25 02:45 ESTNewsStoke Therapeutics (STOK) Presents At 40th Annual J.P. Morgan Virtual Healthcare ConferenceN/A
2021-12-03 21:14 ESTNewsStoke Therapeutics shares data from Phase 1/2a trial for STK-001 in Dravet syndromeN/A
2021-12-01 09:31 ESTNewsWarning: STOK is at high risk of performing badlyN/A
2021-12-01 09:31 ESTNewsStoke Therapeutics (STOK) Investor Presentation -SlideshowN/A
2021-11-23 08:45 ESTNewsStoke Therapeutics up 14% following J.P. Morgan upgrade to overweightN/A
2021-11-08 19:21 ESTNewsStoke Therapeutics EPS misses by $0.02N/A
2021-09-22 07:07 ESTNewsStoke Therapeutics posts interim results from early-stage STK-001 Dravet syndrome studyN/A
2021-08-10 12:23 ESTNewsStoke Therapeutics EPS misses by $0.12N/A
2021-03-30 13:19 ESTNewsStoke Therapeutics gets MHRA greenlight for early-stage Dravet syndrome studyN/A
2021-03-11 20:54 ESTFinancialsCompany financials have been released.Neutral
2021-03-11 12:29 ESTAnalyst RatingThe Analyst Target Price has increased from $63.75 to $65.38.Buy
2021-03-11 00:51 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-11 00:51 ESTAnalyst RatingThe Analyst Target Price has increased from $60.38 to $63.75.Buy
2021-03-11 00:51 ESTEarnings EstimateAn EPS average of -$2.12 is estimated for the 2022 year.Sell
2021-03-10 04:53 ESTFinancialsCompany financials have been released.Neutral
2021-03-07 14:56 ESTNewsSizing Up Stoke TherapeuticsN/A
2021-02-11 08:36 ESTAnalyst RatingThe Analyst Target Price has increased from $59.5 to $60.38.Neutral
2021-02-10 19:01 ESTNewsStoke cut to neutral at Wedbush seeking a ‘better entry point’N/A
2021-01-29 08:37 ESTAnalyst RatingThe Analyst Target Price has increased from $57.63 to $59.5.Neutral
2021-01-15 08:37 ESTAnalyst RatingThe Analyst Target Price has increased from $56.5 to $57.63.Neutral
2020-12-29 08:37 ESTAnalyst RatingThe Analyst Target Price has increased from $54.13 to $56.5.Neutral
2020-12-16 13:07 ESTAnalyst RatingThe Analyst Target Price has increased from $49.13 to $54.13.Neutral
2020-12-14 08:52 ESTAnalyst RatingThe Analyst Target Price has increased from $48.13 to $49.13.Neutral
2020-12-14 08:12 ESTNewsStoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market CapN/A
2020-11-26 21:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-20 03:45 ESTNewsStoke Therapeutics prices $97.5M public offeringN/A
2020-11-19 00:23 ESTNewsStoke Therapeutics -2.7% AH, proposes public offeringN/A
2020-11-17 05:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 05:28 ESTAnalyst RatingThe Analyst Target Price has increased from $47.13 to $48.13.Buy
2020-11-14 21:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 13:26 ESTEarnings EstimateAn EPS average of -$0.44 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-13 13:26 ESTAnalyst RatingThe Analyst Target Price has increased from $41.5 to $47.13.Buy
2020-11-13 10:25 ESTNewsStoke Therapeutics EPS in-lineN/A
2020-11-08 00:59 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:14 ESTFinancialsCompany financials have been released.Neutral
2020-11-04 18:01 ESTInsider TradeHuw M. Nash has directly disposed of 2,536 shares and currently holds 0 shares.Sell

About Stoke Therapeutics, Inc (STOK):

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

STOK Quotes by TradingView

See Advanced Chart

General

  • Name Stoke Therapeutics, Inc
  • Symbol STOK
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 79
  • Fiscal Year EndDecember
  • IPO Date2019-06-19
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.stoketherapeutics.com
View More

Valuation

  • Trailing PE 21.65
  • Price/Book (Most Recent Quarter) 6.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.80
  • Next Year EPS Estimate -$2.10
  • Next Quarter EPS Estimate -$0.44
  • Return on Assets -13%
  • Return on Equity -20%
  • Earnings Per Share -$11.44
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.78 billion
  • EBITDA -22302000
  • PE Ratio -7.4
  • Analyst Target Price $65.38
  • Book Value Per Share $7.14
View More

Share Statistics

  • Shares Outstanding 36.66 million
  • Shares Float 12.64 million
  • % Held by Insiders 170%
  • % Held by Institutions 98.06%
  • Shares Short 3.3 million
  • Shares Short Prior Month 3.37 million
  • Short Ratio 27.54
  • Short % of Float 21%
  • Short % of Shares Outstanding 9%
View More

Technicals

  • 52 Week High $71.58
  • 52 Week Low $17.55
  • 50 Day Moving Average 58.62
  • 200 Day Moving Average 48.97
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Stoke Therapeutics, Inc (STOK) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Stoke Therapeutics, Inc (STOK) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$N/A-$0.42-$0.420.92%
2020-09-302020-11-12$N/A-$0.41-$0.434.58%
2020-06-302020-08-10$N/A-$0.39-$0.36-8.33%
2020-03-312020-05-15$N/A-$0.34-$0.378.87%
2019-12-312020-03-23$N/A-$0.09-$0.3069.63%
2019-09-302019-11-12$N/A-$0.26-$0.285.83%
2019-06-302019-08-14$N/A-$1.54-$1.635.39%

Stoke Therapeutics, Inc (STOK) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 8.9 million N/A N/A 7.22 million 7.09 million
Income Before Tax -14.56 million N/A N/A -11.04 million -10.16 million
Selling General Administrative 5.68 million N/A N/A 4.52 million 3.98 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -14.35 million N/A N/A -11.54 million -11.07 million
Operating Income -14.59 million N/A N/A -11.74 million -11.07 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net 15000 N/A N/A 22000 908000
Net Income From Continuing Operations -14.56 million N/A N/A -11.04 million -10.16 million
Net Income Applicable to Common Shares -14.56 million -13.68 million -12.96 million N/A -10.16 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments -269000 -81000 -610000 N/A N/A
Change to Liabilities 610000 N/A N/A N/A N/A
Total Cash Flow from Investing Activities -269000 N/A N/A N/A N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 673000 369000 198000 N/A N/A
Change to Operating Activities -80000 N/A N/A N/A N/A
Change in Cash -10.47 million -9.36 million -11.18 million N/A N/A
Total Cash from Operating Activities -10.87 million -9.65 million -10.77 million N/A N/A
Depreciation 234000 224000 193000 N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities -360000 N/A N/A N/A N/A
Change to Net Income 2.05 million N/A N/A N/A N/A
Capital Expenditures 269000 81000 610000 N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 11.85 million N/A N/A 6.5 million 4.32 million
Total Stockholder Equity 286.08 million N/A N/A 214.34 million 224.43 million
Other Current Liabilities N/A N/A N/A 54000 N/A
Total Assets 297.93 million N/A N/A 220.84 million 228.75 million
Common Stock 4000 3000 3000 N/A 3000
Other Current Assets 6.62 million 378000 N/A N/A N/A
Retained Earnings -110.28 million -95.72 million -82.03 million -69.07 million -58.04 million
Other Liabilities N/A 665000 1.01 million N/A 221000
Other Assets N/A 205000 205000 N/A 205000
Cash 287.31 million N/A N/A 211.29 million 222.47 million
Total Current Liabilities 11.43 million 6.74 million N/A 5.46 million 4.1 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 2.68 million 4.27 million 4.47 million N/A 2.51 million
Total Current Assets 293.93 million 195.46 million N/A 215.77 million 226.03 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 286.08 million 192.54 million 203.4 million N/A 224.43 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 11.43 million 1.1 million N/A 1.78 million 751000

Stoke Therapeutics, Inc (STOK) Chart:

Stoke Therapeutics, Inc (STOK) News:

Below you will find a list of latest news for Stoke Therapeutics, Inc (STOK) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Stoke Therapeutics, Inc (STOK) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-08-21150CALL0 0232.36TRUE00
2026-08-2117.50CALL0 1187.12TRUE00
2026-08-21200CALL0 35189.95TRUE00
2026-08-2122.50CALL0 3115.02TRUE00
2026-08-21250CALL0 24103.48TRUE00
2026-08-21301.4CALL7 13685.78FALSE-0.8-0.36
2026-08-21350.25CALL3 16394.42FALSE0.250
2026-08-21400CALL0 37114.73FALSE00
2026-08-21450CALL0 13191.11FALSE00
2026-08-21500CALL0 30268.5FALSE00
2026-08-21550CALL0 10292.23FALSE00
2026-08-21150PUT0 0388.1FALSE00
2026-08-2117.50PUT0 20127.11FALSE00
2026-08-21200PUT0 9101.82FALSE00
2026-08-2122.50PUT0 119179.88FALSE00
2026-08-21250PUT0 207269.94FALSE00
2026-08-21302.5PUT0 11645.74TRUE00
2026-08-21350PUT0 3843.93TRUE00
2026-08-21400PUT0 168.12TRUE00
2026-08-21450PUT0 44179.83TRUE00
2026-08-21500PUT0 21106.33TRUE00
2026-08-21550PUT0 0122.16TRUE00
2026-09-18150CALL0 0121.64TRUE00
2026-09-1817.50CALL0 0127.23TRUE00
2026-09-18200CALL0 0105.28TRUE00
2026-09-1822.50CALL0 091.91TRUE00
2026-09-18250CALL0 080.5TRUE00
2026-09-18300CALL0 076.13FALSE00
2026-09-18350CALL0 0106.53FALSE00
2026-09-18400CALL0 0114.58FALSE00
2026-09-18150PUT0 0140.28FALSE00
2026-09-1817.50PUT0 0208.11FALSE00
2026-09-18200PUT0 078.1FALSE00
2026-09-1822.50PUT0 069.47FALSE00
2026-09-18250PUT0 070.78FALSE00
2026-09-18300PUT0 063.98TRUE00
2026-09-18350PUT0 051.48TRUE00
2026-09-18400PUT0 049.22TRUE00
2026-11-20150CALL0 0115.19TRUE00
2026-11-2017.50CALL0 398.01TRUE00
2026-11-20200CALL0 190.33TRUE00
2026-11-2022.50CALL0 077.57TRUE00
2026-11-20250CALL0 578.46TRUE00
2026-11-20300CALL0 2975.68FALSE00
2026-11-20350CALL0 669.9FALSE00
2026-11-20400CALL0 1486.94FALSE00
2026-11-20450CALL0 2101.11FALSE00
2026-11-20500CALL0 5112.92FALSE00
2026-11-20150PUT0 0166.35FALSE00
2026-11-2017.50PUT0 2137.96FALSE00
2026-11-20200PUT0 6475.51FALSE00
2026-11-2022.50PUT0 26080.03FALSE00
2026-11-20250PUT0 072.61FALSE00
2026-11-20300PUT0 3468.93TRUE00
2026-11-20350PUT0 1463.24TRUE00
2026-11-20400PUT0 060.66TRUE00
2026-11-20450PUT0 062.85TRUE00
2026-11-20500PUT0 065TRUE00
2027-02-19150CALL0 1297.7TRUE00
2027-02-1917.50CALL0 083.69TRUE00
2027-02-19200CALL0 076.69TRUE00
2027-02-1922.50CALL0 072.81TRUE00
2027-02-19250CALL0 072.12TRUE00
2027-02-19300CALL0 168.94FALSE00
2027-02-19350CALL0 2370.24FALSE00
2027-02-19400CALL0 066FALSE00
2027-02-19450CALL0 075.37FALSE00
2027-02-19150PUT0 0124.58FALSE00
2027-02-1917.50PUT0 0103.51FALSE00
2027-02-19200PUT0 286.32FALSE00
2027-02-1922.50PUT0 074.01FALSE00
2027-02-19250PUT0 070.33FALSE00
2027-02-19300PUT0 065.3TRUE00
2027-02-19350PUT0 067.33TRUE00
2027-02-19400PUT0 063.84TRUE00
2027-02-19450PUT0 061.09TRUE00

Latest STOK Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST13$10.47
Jun 13, 2022 7:59 PM EST60$10.47
Jun 13, 2022 7:59 PM EST20$10.47
Jun 13, 2022 7:59 PM EST41$10.47
Jun 13, 2022 7:59 PM EST15$10.47

Stoke Therapeutics, Inc (STOK) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2019-04-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019007260/0000000000-19-007260-index.htm
2019-05-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019008485/0000000000-19-008485-index.htm
2019-06-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019009270/0000000000-19-009270-index.htm
2019-06-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019009719/0000000000-19-009719-index.htm
2020-07-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000020006449/0000000000-20-006449-index.htm
2019-07-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000092963819000658/0000929638-19-000658-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000092963820000333/0000929638-20-000333-index.htm
2019-03-26DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1623526/000095012319002845/0000950123-19-002845-index.htm
2019-04-30DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1623526/000095012319003688/0000950123-19-003688-index.htm
2019-04-30DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1623526/000095012319003690/0000950123-19-003690-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000110465920021017/0001104659-20-021017-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000114420419031374/0001144204-19-031374-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000114420419032095/0001144204-19-032095-index.htm
2019-05-23S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312519155301/0001193125-19-155301-index.htm
2019-05-23CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519155321/0001193125-19-155321-index.htm
2019-06-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519163789/0001193125-19-163789-index.htm
2019-06-07S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312519167576/0001193125-19-167576-index.htm
2019-06-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519167579/0001193125-19-167579-index.htm
2019-06-118-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1623526/000119312519170268/0001193125-19-170268-index.htm
2019-06-12S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312519171310/0001193125-19-171310-index.htm
2019-06-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519171314/0001193125-19-171314-index.htm
2019-06-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519173255/0001193125-19-173255-index.htm
2019-06-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519173266/0001193125-19-173266-index.htm
2019-06-19S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1623526/000119312519175848/0001193125-19-175848-index.htm
2019-06-18S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1623526/000119312519175863/0001193125-19-175863-index.htm
2019-06-19424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1623526/000119312519176488/0001193125-19-176488-index.htm
2019-07-01SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1623526/000119312519186323/0001193125-19-186323-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312519220567/0001193125-19-220567-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312519308649/0001193125-19-308649-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520005877/0001193125-20-005877-index.htm
2020-03-23S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1623526/000119312520082470/0001193125-20-082470-index.htm
2020-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520108110/0001193125-20-108110-index.htm
2020-04-21DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1623526/000119312520113542/0001193125-20-113542-index.htm
2020-04-21DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1623526/000119312520113561/0001193125-20-113561-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520139879/0001193125-20-139879-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520160684/0001193125-20-160684-index.htm
2020-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520189990/0001193125-20-189990-index.htm
2020-07-10S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312520191098/0001193125-20-191098-index.htm
2020-07-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312520193961/0001193125-20-193961-index.htm
2020-08-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520221818/0001193125-20-221818-index.htm
2020-08-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520226962/0001193125-20-226962-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520265127/0001193125-20-265127-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021312/0001209191-20-021312-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021314/0001209191-20-021314-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021317/0001209191-20-021317-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021319/0001209191-20-021319-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021321/0001209191-20-021321-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021322/0001209191-20-021322-index.htm
2020-04-153/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120024540/0001209191-20-024540-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120024543/0001209191-20-024543-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm
2020-05-264/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120032142/0001209191-20-032142-index.htm
2020-05-264/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120032146/0001209191-20-032146-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-06-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034721/0001209191-20-034721-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034723/0001209191-20-034723-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034729/0001209191-20-034729-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034731/0001209191-20-034731-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034732/0001209191-20-034732-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034735/0001209191-20-034735-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034737/0001209191-20-034737-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120042004/0001209191-20-042004-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120042007/0001209191-20-042007-index.htm
2020-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm
2020-08-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm
2020-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-10-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm
2020-10-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-06-13CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1623526/000135445719000309/0001354457-19-000309-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219009407/0001493152-19-009407-index.htm
2019-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219009471/0001493152-19-009471-index.htm
2019-06-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219009851/0001493152-19-009851-index.htm
2019-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219014877/0001493152-19-014877-index.htm
2019-11-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219016566/0001493152-19-016566-index.htm
2019-11-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219016926/0001493152-19-016926-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000149315220002386/0001493152-20-002386-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459019032126/0001564590-19-032126-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459019042621/0001564590-19-042621-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459019042891/0001564590-19-042891-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459020012112/0001564590-20-012112-index.htm
2020-03-2310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1623526/000156459020012202/0001564590-20-012202-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459020025636/0001564590-20-025636-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459020025637/0001564590-20-025637-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459020038587/0001564590-20-038587-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459020038905/0001564590-20-038905-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013623/0001567619-19-013623-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013624/0001567619-19-013624-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013625/0001567619-19-013625-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013626/0001567619-19-013626-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013627/0001567619-19-013627-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013628/0001567619-19-013628-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013629/0001567619-19-013629-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013630/0001567619-19-013630-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013631/0001567619-19-013631-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013632/0001567619-19-013632-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013633/0001567619-19-013633-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013662/0001567619-19-013662-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/0001567619-19-013838-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/0001567619-19-013840-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018220/0001567619-19-018220-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018221/0001567619-19-018221-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018222/0001567619-19-018222-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018223/0001567619-19-018223-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018224/0001567619-19-018224-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018225/0001567619-19-018225-index.htm
2019-11-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919021770/0001567619-19-021770-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919021771/0001567619-19-021771-index.htm
2014-11-24DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000162352614000001/0001623526-14-000001-index.htm
2018-11-02DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000162352618000002/0001623526-18-000002-index.htm
2019-06-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1623526/999999999519001367/9999999995-19-001367-index.htm
2020-07-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1623526/999999999520001866/9999999995-20-001866-index.htm
2019-06-03SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1623526/999999999719005333/9999999997-19-005333-index.htm
2019-06-13SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1623526/999999999719005455/9999999997-19-005455-index.htm

Stoke Therapeutics, Inc (STOK) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Stoke Therapeutics, Inc (STOK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 170%
Institutional Ownership: 9806%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-03-02Huw M. NashCOO & CBOSell15,995.0026.37421,852.130.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-06-01Huw M. NashCOO & CBOSell500.0027.4813,742.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2020-07-01Huw M. NashCOO & CBOSell3,800.0023.1587,967.720.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2020-07-07Huw M. NashCOO & CBOSell913.0022.4120,456.860.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042004/0001209191-20-042004-index.htm
2020-07-16Huw M. NashCOO & CBOSell1,900.0025.0647,614.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm
2020-08-03Huw M. NashCOO & CBOSell5,700.0024.73140,943.330.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm
2020-08-28Huw M. NashCOO & CBOSell2,081.0030.0062,430.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm
2020-09-01Huw M. NashCOO & CBOSell700.0028.7120,097.630.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm
2020-09-08Huw M. NashCOO & CBOSell30,718.0030.00921,540.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-09-09Huw M. NashCOO & CBOSell17,201.0030.00516,030.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-10-01Huw M. NashCOO & CBOSell2,300.0034.8680,182.600.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-11-02Huw M. NashCOO & CBOSell2,536.0037.9896,324.890.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-07-07Robin A. WalkerChief Legal Officer, CCO & SecSell941.0022.5021,172.500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042007/0001209191-20-042007-index.htm
2020-11-02Stephen J TulipanoCFOSell14,445.0037.86546,909.371,002.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-06-01Barry TichoChief Medical OfficerBuy131,147.000.6078,688.20131,147.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-03-31Gene LiauEVP Research & Preclinical DevBuy7,500.000.604,500.0013,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm
2020-05-22Gene LiauEVP Research & Preclinical DevSell7,500.0030.00225,000.0013,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevSell1,230.0027.4833,801.5113,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-10-13Gene LiauEVP Research & Preclinical DevSell1,649.0040.0065,960.0013,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm
2020-10-16Gene LiauEVP Research & Preclinical DevSell5,851.0040.00234,041.7613,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevSell7,225.0038.42277,585.9513,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevSell7,875.0026.91211,920.9814,730.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-10-13Gene LiauEVP Research & Preclinical DevBuy1,649.000.60989.4015,149.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm
2020-11-02Stephen J TulipanoCFOSell20,155.0036.79741,448.0315,447.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-03-02Huw M. NashCOO & CBOSell33,148.0025.66850,697.0115,995.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2019-06-21Apple Tree Partners IV, L.P.10% Share HolderBuy1,388,889.0018.0025,000,002.0016,786,713.00https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/0001567619-19-013838-index.htm
2019-06-21Seth Loring HarrisonDirectorBuy1,388,889.0018.0025,000,002.0016,786,713.00https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/0001567619-19-013840-index.htm
2020-11-04Stephen J TulipanoCFOSell16,941.0040.03678,085.5516,929.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-09-09Huw M. NashCOO & CBOBuy17,201.002.1937,670.1917,201.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-06-01Barry TichoChief Medical OfficerSell365.0027.9810,212.70172,662.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-06-01Barry TichoChief Medical OfficerSell1,000.0027.1727,174.00173,027.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-06-01Barry TichoChief Medical OfficerBuy42,880.002.1993,907.20174,027.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-07-16Huw M. NashCOO & CBOBuy1,900.002.194,161.001,900.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm
2020-10-16Gene LiauEVP Research & Preclinical DevBuy5,851.000.603,510.6019,351.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevSell24,775.0037.64932,578.0720,725.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-08-28Huw M. NashCOO & CBOBuy2,081.002.194,557.392,081.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm
2020-05-22Gene LiauEVP Research & Preclinical DevBuy7,500.000.604,500.0021,000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm
2020-06-01Huw M. NashCOO & CBOBuy2,107.002.194,614.332,107.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevSell10,895.0025.82281,314.3522,605.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-10-01Huw M. NashCOO & CBOSell3,400.0034.33116,717.922,300.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-11-03Stephen J TulipanoCFOBuy1,732.004.487,759.362,334.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-11-02Huw M. NashCOO & CBOSell3,164.0036.59115,785.002,536.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-09-08Huw M. NashCOO & CBOBuy30,718.002.1967,272.4230,718.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevBuy20,000.002.1943,800.0033,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2019-06-19RTW INVESTMENTS, LP10% Share HolderBuy555,556.0018.0010,000,008.003,355,466.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219009471/0001493152-19-009471-index.htm
2020-11-04Stephen J TulipanoCFOBuy33,268.004.48149,040.6433,870.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-10-01RTW INVESTMENTS, LP10% Share HolderBuy31,560.0021.96693,029.203,387,026.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219014877/0001493152-19-014877-index.htm
2019-10-30RTW INVESTMENTS, LP10% Share HolderBuy41,438.0028.791,193,004.163,428,464.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-10-31RTW INVESTMENTS, LP10% Share HolderBuy18,747.0028.15527,658.693,447,211.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-11-01RTW INVESTMENTS, LP10% Share HolderBuy8,598.0028.61245,950.093,455,809.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-11-08RTW INVESTMENTS, LP10% Share HolderSell16,434.0028.70471,631.153,544,248.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016926/0001493152-19-016926-index.htm
2020-11-02Stephen J TulipanoCFOBuy35,000.004.48156,800.0035,602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-11-04RTW INVESTMENTS, LP10% Share HolderBuy104,873.0029.243,066,843.093,560,682.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016566/0001493152-19-016566-index.htm
2020-07-01Huw M. NashCOO & CBOBuy3,800.002.198,322.003,800.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevBuy30,497.000.6018,298.2043,997.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevBuy1,503.002.193,291.5745,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-03-02Huw M. NashCOO & CBOBuy42,779.002.1993,686.0149,103.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-06-01Huw M. NashCOO & CBOSell1,607.0027.0843,521.26500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2019-12-16Edward M. MD KayeCEOBuy50,000.000.6030,000.0050,000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120024543/0001209191-20-024543-index.htm
2020-08-03Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm
2020-09-01Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm
2020-10-01Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-11-02Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-11-04Stephen J TulipanoCFOSell11,111.0041.42460,214.295,818.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-12-20Gene LiauEVP Research & Preclinical DevBuy6,000.000.603,600.006,000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm
2020-11-02Stephen J TulipanoCFOSell400.0038.4415,374.00602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-11-03Stephen J TulipanoCFOSell1,732.0039.8468,997.51602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-11-04Stephen J TulipanoCFOSell5,216.0041.97218,909.78602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-03-02Huw M. NashCOO & CBOBuy6,324.000.402,529.606,324.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-09-01Huw M. NashCOO & CBOSell5,000.0027.60138,015.00700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm